Kateri Moore, DVM Email Kateri Moore
- PROFESSOR | Cell, Developmental & Regenerative Biology
Aging, Bioinformatics, Cell Adhesion, Cell Biology, Cell Cycle, Cell Division, Cellular Differentiation, Developmental Biology, Epigenetics, Gene Discovery, Genomics, Hematopoiesis, Mathematical Modeling of Biomedical Systems, Molecular Biology, Stem Cells, Transcription Factors, Transgenic Mice
Multi-Disciplinary Training Area
Development, Regeneration, and Stem Cells [DRS]
BS, Kansas State University
DVM, Kansas State University
Post Doctoral, Baylor College of Medicine
EnglishDownload the CV
National Research Service Award
National Institutes of Health
Hematopoietic Stem Cells Normal and Reprogrammed
Specific Clinical/Research Interest: Stem Cells/Microenvironment/Stem Cell Niche, Molecular regulation of hematopoietic stem cell self renewal and differentiation, molecular interaction of stem cells and microenvironmental elements. Direct differentiation of somatic cells into hematopoietic stem cells.
Current Students: Jeffrey Bernitz
Research Personnel: Ying Liu
Summary of Research Studies: Primary research interest is in defining the cellular and molecular nature of the hematopoietic stem cells (HSCs) and in particular the molecular cross-talk between stem cells and their niche. Approach is to use mouse models to study HSC during normal homeostasis and after stress. Also using specific factors to directly induce HSCs from somatic cells to develop patient specific stem cells and differentiated blood products for cell replacement therapies.
Bernitz JM, Kim HS, MacArthur B, Sieburg H, Moore K. Hematopoietic Stem Cells Count and Remember Self-Renewal Divisions. Cell 2016 11; 167(5).
Bernitz JM, Daniel MG, Fstkchyan YS, Moore K. Granulocyte colony-stimulating factor mobilizes dormant hematopoietic stem cells without proliferation in mice. Blood 2017 Apr; 129(14).
Daniel MG, Pereira CF, Bernitz JM, Lemischka IR, Moore K. Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program. Journal of visualized experiments : JoVE 2016 Dec;(118).
Pereira CF, Chang B, Gomes A, Bernitz J, Papatsenko D, Niu X, Swiers G, Azzoni E, de Bruijn MF, Schaniel C, Lemischka IR, Moore KA. Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells. Developmental Cell 2016 Mar; 36(5).
Daniel MG, Lemischka IR, Moore K. Converting cell fates: generating hematopoietic stem cells de novo via transcription factor reprogramming. Annals of the New York Academy of Sciences 2016 Jan;.
Daniel MG, Pereira CF, Lemischka IR, Moore KA. Making a Hematopoietic Stem Cell. Trends in Cell Biology 2015 Oct;.
Pereira CF, Lemischka IR, Moore K. 'From blood to blood': de-differentiation of hematopoietic progenitors to stem cells. The EMBO journal 2014 Jun;.
Pereira CF, Lemischka IR, Moore K. . Cell Cycle 2014 Feb 13(3):335-336.
Qiu J, Papatsenko D, Niu X, Schaniel C, Moore K. Divisional History and Hematopoietic Stem Cell Function during Homeostasis. Stem Cell Reports 2014 Apr; 2(4).
Bernitz JM, Moore KA. Uncovering the origins of a niche. eLife 2014 3.
Pereira CF, Chang B, Qiu J, Niu X, Papatsenko D, Hendry CE, Clark NR, Nomura-Kitabayashi A, Kovacic JC, Ma'ayan A, Schaniel C, Lemischka IR, Moore K. Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell 2013 Aug; 13(2).
Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, Pereira CF, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 2012 Aug; 11(2).
Pereira CF, Lemischka IR, Moore K. Reprogramming cell fates: insights from combinatorial approaches. Annals of the New York Academy of Sciences 2012 Aug; 1266.
Schaniel C, Sirabella D, Qiu J, Niu X, Lemischka IR, Moore KA. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 2011 Sep; 118: 2420-2429.
Glauche I, Moore K, Thielecke L, Horn K, Loeffler M, Roeder I, Miyazaki K, Moore KA, Honda Z, Suda T, Lemischka IR. Stem cell proliferation and quiescence--two sides of the same coin. PLoS Computational Biology 2009 Jul; 5(7).
Schaniel C, Moore KA, Thielecke L, Horn K, Loeffler M, Roeder I. Genetic models to study quiescent stem cells and their niches. Annals of the New York Academy of Sciences 2009 Sep; 1176.
Moore KA, Lemischka IR. Stem cells and their niches. Science 2006 Mar 31; 311(5769): 1880-1885.
Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002 Oct 18; 298(5593): 601-604.
Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci U S A 2002 Oct 1; 99(20): 13061-13066.
Phillips RL, Ernst RE, Brunk B, Ivanova N, Mahan MA, Deanehan JK, Moore KA, Overton GC, Lemischka IR. The genetic program of hematopoietic stem cells. Science 2000 Jun 2; 288(5471): 1635-1640.
Moore KA, Pytowski B, Witte L, Hicklin D, Lemischka IR, Deanehan JK, Moore KA, Overton GC, Lemischka IR. Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs. Proc Natl Acad Sci USA 1997 Apr 15; 94(8): 4011-4016.
Moore KA, Ema H, Lemischka IR, Hicklin D, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997 Jun 15; 89(12): 4337-4347.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Moore did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.